CRISPR knockout screening identifies combinatorial drug targets in pancreatic cancer and models cellular drug response

Código QR

CRISPR knockout screening identifies combinatorial drug targets in pancreatic cancer and models cellular drug response

Predicting the response to chemotherapy is a major goal of cancer research. Here the authors use CRISPR knockout screens in pancreatic ductal adenocarcinoma cells to identify deletions synergistic with MEK inhibitors.

Guardado en:

Detalles Bibliográficos
Autores principales:	Karol Szlachta, Cem Kuscu, Turan Tufan, Sara J. Adair, Stephen Shang, Alex D. Michaels, Matthew G. Mullen, Natasha Lopes Fischer, Jiekun Yang, Limin Liu, Prasad Trivedi, Edward B. Stelow, P. Todd Stukenberg, J. Thomas Parsons, Todd W. Bauer, Mazhar Adli
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2018
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/5878576fa2b34029942f52a332a9c423
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Descripción
Sumario:	Predicting the response to chemotherapy is a major goal of cancer research. Here the authors use CRISPR knockout screens in pancreatic ductal adenocarcinoma cells to identify deletions synergistic with MEK inhibitors.